147 results
Page 2 of 8
6-K
EX-99.1
46tf3 ucq8ia8
26 Oct 23
Current report (foreign)
6:20am
6-K
EX-99.1
1qa1 tt3r8
18 Oct 23
Current report (foreign)
6:21am
6-K
EX-99.1
jz8tykwh3bv7yj
18 Oct 23
Current report (foreign)
6:20am
6-K
pcq3aa0yrbv
2 Oct 23
Current report (foreign)
6:17am
6-K
dwyts6v mewxm
28 Sep 23
Current report (foreign)
6:17am
6-K
6gy85yky5v br225f
11 Sep 23
Current report (foreign)
6:50am
6-K
EX-99.1
mf3p8ve812z1c86
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
95qx3
6 Jul 23
Current report (foreign)
6:18am
6-K
6roe9432dxg4 evbs
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
bw8siwv1 8bzxeuv9l0
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
s4s3y6
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
gv8kibxrbmmj56nn
30 May 23
Current report (foreign)
6:11am
6-K
aujxpzjo3i0hah
17 May 23
Current report (foreign)
6:02am
6-K
cyhib l2qpx
11 May 23
Current report (foreign)
6:10am
6-K
9lh92inafsira7myc
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
p5jzlugql9 nc
11 May 23
Current report (foreign)
6:07am
6-K
66z3jq31ssbn3l0yqsq
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
gw2qdx pal
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
siovxrs
8 Dec 22
Current report (foreign)
6:46am